Currently existing classes of medication for the treatment of Alzheimer’s disease (AD), namely acetylcholinesterase inhibitors such as tacrine, rivastigmine, and galantamine and the N-methyl-D-aspartate receptor antagonist memantine have limited clinical benefits in terms of enhanced cognition and eventually do not prevent the disease progression (DeKosk, 2003[14]; Casey et al., 2010[7]; Stuchbury and Münch, 2005[54]). This evidence concerns the gene ACHE and Alzheimer disease.